Quit Smoking Text Message Study

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06111755
Collaborator
American Lung Association (Other)
200
2
19

Study Details

Study Description

Brief Summary

This project will address research gaps and advance the science of smoking cessation by conducting a randomized controlled trial of an evidence-based, population-level quit smoking text messaging program with or without a smartband.

Condition or Disease Intervention/Treatment Phase
  • Other: SmokefreeTXT
  • Device: Smartband
N/A

Detailed Description

Aim 1 of this study is to test within-treatment effects for smoking cessation. The primary outcome will be biochemically (cotinine)-confirmed 7-day point-prevalence abstinence (PPA) at end of treatment (8 weeks). Secondary outcomes will be percent days smoke-free, time to relapse, and rated treatment satisfaction.

Aim 2 of this study is to explore sex/gender differences in treatment effects for smoking cessation. Given established sex/gender differences in smoking behavior and cessation,randomization will be stratified by sex/gender and we will measure effects of sex/gender on outcomes. Effect sizes will be estimated for smoking outcomes by sex.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluating Digital Health Interventions To Promote Smoking Cessation
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: SmokefreeTXT

Daily smokers for at least 6 months who report an interest in quitting will be randomized to receive the National Cancer Institute's SmokefreeTXT.

Other: SmokefreeTXT
National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.

Experimental: SmokefreeTXT + smartband

Daily smokers for at least 6 months who report an interest in quitting will be randomized to receive the National Cancer Institute's SmokefreeTXT + smartband.

Other: SmokefreeTXT
National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.

Device: Smartband
A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.

Outcome Measures

Primary Outcome Measures

  1. Number of participants with cotinine confirmed 7-day point-prevalence abstinence (PPA) at end of treatment (8 weeks) [8 weeks]

    7-day PPA at end of treatment with be confirmed via cotinine testing in saliva

Secondary Outcome Measures

  1. Change in cigarettes smoked per day [baseline, 4 weeks and 8 weeks]

    Change in average number cigarettes smoked per day by self report

  2. Percent days smoke-free [up to 8 weeks]

    Percentage of smoke-free days by self report

  3. Average number of days to relapse [2 weeks post quit date]

    Relapse is defined as 7 consecutive days of smoking after quitting and will be measured using self-report or smartband detection. This will be assessed after their quit date.

  4. Treatment satisfaction assessed using the User Burden Scale [up to 8 weeks]

    User burden scale: User burden will be assessed using items on a 5 point Likert scale with scores from 0 (not at all/never) to 4 (extremely/all of the time). Means will be reported for 6 subscales (difficulty of use, physical, time and social, mental and emotional, privacy, financial) and an overall scale range 0 to 80, with higher scores indicating more user burden.

  5. Treatment satisfaction assessed using the System Usability Scale [up to 8 weeks]

    System usability scale: Uses 10 items ranked from 1 (strongly disagree) to 5 (strongly agree) with a total score 0-100 with higher score indicating better system usability.

  6. Treatment satisfaction assessed using the Mobile Application Rating Scale User version [up to 8 weeks]

    This 20-item scale uses 5-point multiple choice ratings and has 6 subscales. Scores are reported as: 1) mean app quality, which is the mean score for the 4 subscales engagement, functionality, aesthetics, information quality; 2) mean of the app subjective quality subscale, and 3) mean of the perceived impact subscale. Higher scores indicate higher app quality, higher app subjective quality, and higher perceived impact. Mean scores range 1-5, with higher scores indicate higher app quality, higher app subjective quality, and higher perceived impact.

  7. Treatment satisfaction assessed using the Acceptability of Intervention Measure [up to 8 weeks]

    Acceptability of Intervention Measure includes three scales for Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). Each measure includes 4 items rated on a 5-point Likert scale from "completely disagree" to "completely agree" and average subscale responses are reported (out of 5) with higher scores indicating greater acceptability, appropriateness, or feasibility.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • daily smokers for at least 6 months

  • report an interest in quitting smoking.

Exclusion Criteria:
  • reporting being currently enrolled in another quit smoking program

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yale University
  • American Lung Association

Investigators

  • Principal Investigator: Kathleen A Garrison, PhD, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT06111755
Other Study ID Numbers:
  • 2000035868
  • IA-1049344
First Posted:
Nov 1, 2023
Last Update Posted:
Nov 1, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 1, 2023